65 results on '"Zile, Michael R"'
Search Results
2. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
3. Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation
4. Abstract 16755: Changes in Mid-Regional Pro-Adrenomedullin During Treatment With Sacubitril/Valsartan
5. Abstract 13828: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARADIGM-HF Proteomic Sub-Study
6. Abstract 12470: Sacubitril/Valsartan in Patients With Heart Failure and Deterioration of Kidney Function to Estimated Glomerular Filtration Rate Less Than 30ml/min/1.73m2: Insights From PARAGON-HF and PARADIGM-HF
7. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
8. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
9. Left Ventricular Gene Expression in Heart Failure With Preserved Ejection Fraction—Profibrotic and Proinflammatory Pathways and Genes
10. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
11. A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone
12. Abstract 17176: Burden and Prognostic Importance of Heart Failure Signs and Symptoms - Differences in Heart Failure With Preserved versus Reduced Ejection Fraction
13. Abstract 16928: Discordant Mechanisms in Heart Failure and Hypertrophy
14. Abstract 16514: Impact of Chronic Obstructive Pulmonary Disease on Outcomes in Heart Failure With Preserved Ejection Fraction: An Analysis of PARAGON-HF
15. Abstract 15762: Intensive Weight Management Improves Functional Capacity in Heart Failure With Preserved Ejection Fraction
16. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF
17. Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation
18. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction
19. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction
20. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF
21. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status
22. Heart Failure With Preserved Ejection Fraction in the Young
23. IGFBP7 (Insulin-Like Growth Factor–Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure
24. Abstract 16903: Circulating Growth Differentiation Factor 15 (GDF-15) in Patients With Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF
25. Abstract 14204: Heart Failure With Preserved Ejection Fraction in the Young
26. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy
27. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation
28. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)
29. Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure
30. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction
31. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap
32. Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan
33. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
34. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy
35. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response
36. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
37. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study
38. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction
39. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
40. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction
41. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction
42. Impaired left atrial function in heart failure with preserved ejection fraction
43. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
44. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
45. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)
46. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial
47. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction
48. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction
49. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)
50. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.